Eli Lilly (NYSE: LLY) Just Broke Out to a Record High and Could Rise 8%–17%

Eli Lilly and Company (NYSE: LLY) just broke out of a six-month uptrend channel to a fresh all-time high on a +6.63% single-session surge — and looks headed even higher.

As we’ll get to just ahead, the combination of a blowout quarter that sent its full-year sales outlook sharply higher, a next-generation weight-loss drug that just beat a major rival head-to-head, and a fresh technical breakout makes LLY one of the more interesting setups on the board. Here’s what’s going on…

The Themes Behind the Move

Eli Lilly is an Indianapolis-based pharmaceutical giant, founded in 1876, that discovers, develops, and sells medicines across diabetes and obesity, cancer, immunology, and neuroscience — including diabetes drug Mounjaro, weight-loss drug Zepbound, breast cancer treatment Verzenio, and Alzheimer’s drug Kisunla.

In plain English, Lilly is the company at the center of the weight-loss drug boom. Mounjaro and Zepbound are two brand names for the same medicine, tirzepatide — part of the GLP-1 family of drugs, which mimic natural gut hormones that regulate blood sugar and appetite — and together they now account for roughly two-thirds of Lilly’s revenue. Its business hinges on how fast demand for these drugs keeps growing, how well prices hold up as access widens, and whether its next wave of medicines — a weight-loss pill and a next-generation injectable — can extend its lead.

LLY’s latest move reflects a powerful confluence of developments — financial, clinical, and commercial — that have come together in rapid succession to reinforce the company’s position as the leader of one of the fastest-growing markets in medicine.

If needed, swipe or scroll sideways to view the full table.

Put it all together, and LLY is looking less like a crowded mega-cap that’s already priced for perfection and more like a growth engine that’s still accelerating — with sales up 39%, a full-year outlook lifted by $5.5 billion, a weight-loss pill gaining traction, and a next-generation drug that just beat its biggest rival’s flagship head-to-head.

The story is getting stronger, but the chart is what could determine whether this move has more room to run in the near term. Here are the bullish technical signals traders should be watching now.

Bullish Technical Signals

#1 Uptrend Channel Breakout: Since early May, LLY has climbed inside a well-defined ascending channel (marked in purple on the daily chart). It has respected both rails with unusual discipline: a rejection at the upper boundary in mid-August, a clean bounce off the lower rail in September, and then a steady grind back to the top. Yesterday’s session settled the question. After nearly a week of tight, small-bodied candles pressed directly beneath the upper rail, price opened at the trendline ($1,332.73) and drove through it, closing at $1,373.70 for a +6.63% gain on 4.37M shares, a clear step up from the recent volume run-rate. That pattern of a coil followed by a release is what separates a genuine breakout from a probe. A break above the top of an already-rising channel isn’t a reversal signal. It’s an acceleration: demand is now outrunning the slope of the prior trend. The measured move adds weight to the target. The channel is roughly $165 wide at the breakout point, and projecting that from the ~$1,335 rail lands near $1,500, the same zone as our first price target. The honest caveat: the candle left a long upper wick to $1,408.38, showing some profit-taking in the $1,400 zone. That is why the breakout entry sits at $1,385 (a confirmation level inside that wick) and the pullback entry at $1,345 lines up with a retest of the broken rail as support.

LLY – Daily Chart

#2 Price above MAs: LLY trades well above both its 50-day SMA ($1,193.68) and 200-day SMA ($1,089.52). The 50-day has held above the 200-day since early summer, preserving the golden-cross alignment, and both averages are sloping firmly higher. This is a mature, orderly uptrend, not a fledgling one. The averages also form a tiered support structure. The first line of defense is the broken channel rail near $1,335–$1,345. Below that, the 50-day near $1,194 is converging with the channel’s lower rail, a meaningful confluence that marks the trend’s structural floor. One point worth stating plainly: after yesterday’s surge, price sits ~15% above the 50-day and ~26% above the 200-day, so the stock is extended in the near term. A controlled pullback toward the breakout zone would be a healthy retest, not a crack in the thesis, which is exactly the scenario the dual-entry structure is built to capture.

#3 Bullish ADX and DI: The directional read here is about as one-sided as this indicator gets. +DI (41.29) towers over –DI (10.62), a spread of more than 30 points. That reflects outright buyer dominance, not a modest tilt, and a –DI near 10 says sellers have all but stepped away. The ADX line (39.76) adds the strength dimension. It has surged from a compressed sub-20 reading in late September to nearly 40, crossing the 25 threshold that separates trending markets from drifting ones along the way. ADX is direction-agnostic, so this steep climb confirms that the October advance is a trend with real force behind it, not range-bound noise. ADX now sits just beneath +DI and is still rising, which keeps the momentum read constructive. The level to watch going forward is whether ADX overtakes +DI and then rolls over, the classic early sign of trend fatigue. For now, the line is still climbing, and stacked against the channel breakout, structure and trend strength point the same way.

#4 Bullish MACD: The MACD line (38.96) is running comfortably above its signal line (28.29), with the histogram at 10.67. The underlying crossover fired in early-to-mid October from just above the zero line, which is the highest-quality zone for a MACD cross because it marks momentum turning before the move becomes stretched. Since then, both lines have climbed steadily into positive territory, confirming that the trend is established rather than merely starting. What gives today’s reading extra weight is the histogram. After narrowing briefly during last week’s consolidation beneath the channel rail, it expanded again on the breakout session. The spread between short- and long-term momentum is widening once more, a sign of re-acceleration rather than a late-cycle fade. The MACD line is also pushing back toward its June highs near 40, so momentum is matching the strength of the summer advance just as price breaks to new highs.

#5 Above Support Area: Zooming out, the weekly chart shows LLY lifting cleanly off a resistance-turned-support level near $1,256.85 (pink dotted line). This zone capped price through the July–October consolidation, and this week it did the opposite: the weekly candle dipped to $1,260.34, held just above the level, and then reversed into a +7.87% advance to $1,373.70. Levels that invert their role and then hold on the first test are the ones the market respects. The longer-term structure is equally strong. LLY trades far above both its rising 50-week SMA ($1,088.40) and 200-week SMA ($786.99), a picture of a primary uptrend that has been intact since 2024. The 50-week ($1,088) and the daily 200-day ($1,090) are nearly identical, so the deeper backstop is reinforced across timeframes. Finally, this move takes LLY into all-time-high territory, where there is no historical overhead supply left to work through. When the daily breakout and the weekly support hold line up this cleanly, the signal carries more weight than either would alone.

LLY – Weekly Chart

#6 Bullish RSI: The weekly RSI (69.35) sits well above its 50 midline and continues to slope higher, and the two parts of that read reinforce each other. Holding above 50 confirms that buyers own the momentum edge on the higher timeframe. The steep climb from the low-50s in September shows that edge is expanding, not stalling. RSI is also running about 10 points ahead of its own signal average (59.04), which points to accelerating momentum rather than a drift. The honest nuance: at ~69, RSI is knocking on the 70 overbought threshold. The last time it pushed well beyond that level, in mid-2024, the stock spent the following months consolidating. In strong primary trends, weekly RSI can hold in the 70s for extended stretches, so the reading isn’t a sell signal. It does reinforce that the pullback entry offers the better risk profile than chasing strength.

#7 Bullish Aroon: The weekly Aroon shows the cleanest possible bullish configuration. Aroon Up is pinned at 100%, meaning LLY printed a fresh 14-week high (and in this case an all-time high) this very week. Aroon Down sits at just 14.29%, which means the most recent 14-week low is now 12 weeks in the past. The wide gap between the two lines reflects a market where new highs are arriving constantly and new lows have become distant history, a clear sign of a well-established trend. Aroon Up has also snapped back to its ceiling after a brief dip during the September pullback, confirming that the consolidation was a pause within the trend rather than a change in its character. Taken together with the support hold and the rising RSI, all three weekly signals confirm the daily breakout.

Risks to Consider

Even strong setups can fail, especially in a premium-valued mega-cap like Eli Lilly. A few things could knock the stock off course:

• A breakdown back inside the uptrend channel on heavy volume — especially a close below the $1,257–$1,270 support zone — would invalidate the breakout thesis
• Negative company-specific news, broader market weakness, or regulatory and drug-pricing changes across the pharmaceutical sector could trigger a sell-off
• Short-term extension and profit-taking — the stock is ~15% above its 50-day average and pulled back from a $1,408.38 intraday high, while pre-earnings options flow was only modestly bullish on net (about +$1.4 million in net directional premium)
• Premium valuation — LLY trades at roughly 44.6x trailing and 31x forward earnings, per Stock Analysis, leaving the shares vulnerable to multiple compression even if the business keeps executing
• GLP-1 pricing pressure — worldwide realized prices fell 15% in Q3, and programs like the Medicare GLP-1 Bridge that widen access can also intensify net-price pressure, with program terms subject to change
• Revenue concentration — Mounjaro and Zepbound account for roughly 66% of quarterly revenue, exposing Lilly to concentrated pricing, patent, and competitive risk
• Earnings quality and capital commitments — Q3 included about $900 million in favorable one-time revenue items (including $410 million in nonrecurring Jardiance milestones), acquired-R&D charges reached roughly $4.2 billion per the Q3 release, and the $50 billion+ manufacturing buildout requires years of sustained execution
• Competition and clinical execution — Foundayo’s $184 million Q3 missed expectations amid competition from Novo Nordisk’s oral Wegovy, and retatrutide remains unapproved, with higher-dose discontinuation rates of 7.9% versus 2.7% for Ozempic worth monitoring

The Bottom Line

LLY is breaking out of a six-month uptrend channel on the daily chart while lifting cleanly off a resistance-turned-support level on the weekly — a dual-timeframe technical setup that historically signals the start of a sustained move higher.

The fundamental story underneath the chart is just as strong: a 39% jump in quarterly revenue, a $5.5 billion boost to full-year sales guidance, and a head-to-head clinical win over Ozempic.

Combine that with multiple catalysts staggered through the rest of 2026 and into 2027 — an expected Foundayo diabetes decision in Q4, Lilly’s Innovation Day on December 7, the planned retatrutide FDA filing in Q1 2027, and Q4 results with first 2027 guidance in early 2027 — and LLY looks like one of the more compelling risk-reward setups on the board right now.

If this is a trade you want to get in on, here’s how we’d play it. Below you’ll find our two entry options — one on the breakout, one on a pullback — both price targets that imply 8%–17% potential upside, and the stop-losses we’re using to manage the downside.

Recommended Trade Setup

Because LLY is extended after its earnings surge, we’re laying out two ways to play it: a breakout entry for traders who want confirmation of continued strength, and a pullback entry — which offers the better risk profile — for those willing to wait for a retest of the broken channel.

Case 1: On Breakout

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $60.00 per share, the target rewards are about $115.00 and $195.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on Trade Invalidation: This recommendation stays active as long as the technical structure holds. If LLY drops to or below the $1,325.00 stop-loss before the $1,385.00 entry triggers, the trade is automatically void — the support underpinning the thesis would have broken, and the risk-reward setup would no longer justify entry.

Case 2: On Pullback

If needed, swipe or scroll sideways to view the full table.

For a risk of approximately $75.00 per share, the target rewards are about $155.00 and $235.00 per share. That makes this roughly a 1:2 and 1:3 risk-reward trade. In other words, the setup offers nearly 2x to 3x more potential upside than downside.

Note on the Stop-Loss: The $1,270.00 stop sits at the upper edge of the $1,257–$1,270 support zone. A close below it would mean LLY has surrendered the entire breakout and slipped back into its prior consolidation range.

Happy Trading!
Tara and Greg